

August 1, 2017

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai – 400001

Subject: Intimation of Conference Call for Investors/ Analyst for Q1 FY18

Ref: Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015

Dear Sir/Madam,



Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015, please find attached the invite of the Conference Call for Investors/ Analysts to be held on Monday, August 07, 2017 at 5.00 PM IST to discuss financial and operating performance for Q1 FY 18.

You are requested to take note of the above.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited



Rajat Kalra
Company Secretary & Legal Head

Encl: As above

Q1 FY18 Earnings Conference Call Monday, August 07, 2017 at 5:00 pm IST

Gurgaon, August 01, 2017:

Dr Lal PathLabs Ltd. (DLPL) will be hosting a conference call to discuss its Q1 FY18 results. DLPL will be represented by (Hony.) Brig. Dr. Arvind Lal - Chairman and Managing Director, Dr. Om Prakash Manchanda - Whole-time Director and CEO and Mr. Dilip Bidani - CFO.

The conference call will be initiated with a brief discussion by the management on the Q1 FY18 financial and operating performance, which will be announced on the same day. Following this, there will be an opportunity for participants to get their queries addressed during the call.

Details of the conference call are as follows:

Time	<ul style="list-style-type: none">• 05:00 pm IST on Monday, August 07, 2017
Conference dial –in – India Access	<ul style="list-style-type: none">• +91 22 3938 1071
Local Access Number	<ul style="list-style-type: none">• 3940 3977 Available in - Ahmedabad, Bangalore, Chandigarh, Chennai, Gurgaon (NCR), Hyderabad, Kochi/Cochin, Kolkata, Lucknow, Pune. Accessible from all carriers.
Conference dial-in – International Toll Number	<ul style="list-style-type: none">• USA - 13233868721
	<ul style="list-style-type: none">• UK - 442034785524
	<ul style="list-style-type: none">• Singapore - 6531575746
	<ul style="list-style-type: none">• Hong Kong - 85230186877
Replay	<ul style="list-style-type: none">• +91 22 3065 2322• 46056 (passcode)• Valid from August 07, 2017 to August 14, 2017

-ENDS-

About Dr Lal PathLabs Limited (DLPL)

Dr Lal PathLabs Limited is one of India's leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. The catalogue of services includes 1,110 test panels, 2,028 pathology tests and 1,561 radiology and cardiology tests.

As on March 31, 2017 DLPL's has 189 clinical labs (including National Reference Lab at Delhi), 1,759 Patient Service Centers (PSCs) and 5,021 Pick-up Points (PUPs). In FY16 & FY17, DLPL collected and processed approximately 26.3 million samples and 29.3 million samples from approximately 12.0 million and 13.3 million patients, respectively.

Additional information on Dr Lal PathLabs Limited:

Corporate Identification No: L74899DL1995PLC065388

Website: <https://www.lalpathlabs.com/>

For further information please contact:

Dilip Bidani
Dr Lal PathLabs Limited
Tel: +91 124 301 6500
Fax: +91 124 423 4468
E-mail: dilip.bidani@lalpathlabs.com

Siddharth Rangnekar / Urvashi Butani
CDR, India
Tel: +91 22 66451209 / 1219
Fax: +91 22 66451213
Email: siddharth@cdr-india.com
urvashi@cdr-india.com